Zalcaren 50 mg Injection
PDF Leaflet Revision Date: 13 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and ovarian cancer.
Dosage (summary)
IV doses vary from 8 mg/mu00b2 to 200 mg/mu00b2, adjusted based on blood counts.
Special Populations
- Renal impairment
- Elderly
- Children
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Nalidixic acid
- Ciclosporin
- Live vaccines
Contraindications
- Previous allergic reaction to melphalan
- Pregnancy
- Lactation
- Live attenuated vaccines
Common side effects
- Nausea
- Vomiting
- Thrombocytopenia
- Neutropenia
- Alopecia
Counselling Points
- Avoid pregnancy during treatment
- Monitor for signs of bleeding
- Report any allergic reactions immediately
Serious warnings
- Myelosuppression risk
- Leukaemogenic potential
- Cytotoxic handling precautions
Important Disclaimer
The Zalcaren 50 mg Injection professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
